ATE256143T1 - 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen - Google Patents

2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Info

Publication number: ATE256143T1
Authority: AT; Austria
Prior art keywords: phosphoramidites; production; alkyl; alkyl nucleosides; guanosine
Prior art date: 1992-07-23

Application number

AT93917287T

Other languages

English (en)

Inventor

Daniel Peter Claude Mcgee

Phillip Dan Cook

Charles John Guinosso

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-23

Filing date

1993-07-20

Publication date

2003-12-15

1992-07-23 Priority claimed from US07/918,362 external-priority patent/US5506351A/en

1992-10-27 Priority claimed from US07/967,267 external-priority patent/US7101993B1/en

1993-07-20 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of ATE256143T1 publication Critical patent/ATE256143T1/de

Links

238000000034 method Methods 0.000 title abstract 4
239000002777 nucleoside Substances 0.000 title 1
150000008300 phosphoramidites Chemical class 0.000 title 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 3
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
229940029575 guanosine Drugs 0.000 abstract 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 abstract 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 abstract 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 abstract 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
229940045145 uridine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT93917287T 1992-07-23 1993-07-20 2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen ATE256143T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US07/918,362 US5506351A (en)	1992-07-23	1992-07-23	Process for the preparation of 2'-O-alkyl guanosine and related compounds
US07/967,267 US7101993B1 (en)	1990-01-11	1992-10-27	Oligonucleotides containing 2′-O-modified purines
US96884992A	1992-10-30	1992-10-30
PCT/US1993/006807 WO1994002501A1 (en)	1992-07-23	1993-07-20	Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

Publications (1)

Publication Number	Publication Date
ATE256143T1 true ATE256143T1 (de)	2003-12-15

Family

ID=27420643

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT93917287T ATE256143T1 (de)	1992-07-23	1993-07-20	2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
AT02076058T ATE299509T1 (de)	1992-07-23	1993-07-20	Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02076058T ATE299509T1 (de)	1992-07-23	1993-07-20	Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen

Country Status (7)

Country	Link
EP (2)	EP1223173B1 (de)
JP (3)	JP3015464B2 (de)
AT (2)	ATE256143T1 (de)
AU (1)	AU4684993A (de)
CA (1)	CA2140428C (de)
DE (2)	DE69333842T2 (de)
WO (1)	WO1994002501A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
ES2128535T3 (es) *	1993-05-12	1999-05-16	Novartis Ag	Nucleosidos y oligonucleotidos con grupos 2'-eter.
US5955591A (en) *	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
AT407639B (de) *	1993-12-13	2001-05-25	Christian Dr Noe	Modifizierte oligonukleotide, verfahren zu ihrer herstellung und verwendung als wirkstoffe zur herstellung von arzneimitteln
US5756707A (en) *	1994-12-13	1998-05-26	Perseptive Biosystems, Inc.	Method of making 2'-O-alkyl pyrimidine ribonucleosides
US6420549B1 (en)	1995-06-06	2002-07-16	Isis Pharmaceuticals, Inc.	Oligonucleotide analogs having modified dimers
DK0882061T3 (da)	1996-02-14	2004-09-27	Isis Pharmaceuticals Inc	Sukkermodificerede gapped oligonukleotider
CA2256765A1 (en) *	1996-06-06	1997-12-11	Novartis Ag	2'-substituted nucleosides and oligonucleotide derivatives
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
EP0912767B1 (de) *	1996-07-16	2006-09-13	Gen-Probe Incorporated	Verfahren zum nachweis und amplifikation von nukleinsäuresequenzen unter verbrauch von modifizierten oligonukleotiden mit erhöhter zielschmelztemperatur (tm)
US7070925B1 (en)	1996-07-16	2006-07-04	Gen-Probe Incorporated	Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6025133A (en) *	1996-12-30	2000-02-15	Gen-Probe Incorporated	Promoter-sequestered oligonucleoside and method of use
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6127533A (en) *	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
DE19741715A1 (de) *	1997-09-22	1999-03-25	Hoechst Ag	Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6043352A (en) *	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US6673912B1 (en)	1998-08-07	2004-01-06	Isis Pharmaceuticals, Inc.	2′-O-aminoethyloxyethyl-modified oligonucleotides
US6403779B1 (en)	1999-01-08	2002-06-11	Isis Pharmaceuticals, Inc.	Regioselective synthesis of 2′-O-modified nucleosides
EP1198592A4 (de) *	1999-07-06	2002-09-18	Isis Pharmaceuticals Inc	Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten.
US6261840B1 (en)	2000-01-18	2001-07-17	Isis Pharmaceuticals, Inc.	Antisense modulation of PTP1B expression
US20020055479A1 (en)	2000-01-18	2002-05-09	Cowsert Lex M.	Antisense modulation of PTP1B expression
JP3596669B2 (ja) *	2000-08-08	2004-12-02	ヤマサ醤油株式会社	２’−ｏ−アルキルグアノシンの製造法
CA2451643C (en)	2001-06-21	2012-11-13	Isis Pharmaceuticals, Inc.	Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en)	2001-07-25	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of C-reactive protein expression
US20030096772A1 (en)	2001-07-30	2003-05-22	Crooke Rosanne M.	Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
NZ577565A (en)	2001-10-09	2010-10-29	Isis Pharmaceuticals Inc	Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en)	2001-10-09	2004-06-15	Isis Pharmaceuticals, Inc.	Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
AU2003278957A1 (en)	2002-09-26	2004-04-23	Amgen, Inc.	Modulation of forkhead box o1a expression
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
SI1569695T1 (sl)	2002-11-13	2013-08-30	Genzyme Corporation	Protismiselna modulacija ekspresije apolipoproteina B
AU2003294281B2 (en)	2002-11-13	2010-05-20	Kastle Therapeutics, Llc	Antisense modulation of apolipoprotein B expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
ES2385924T3 (es)	2006-02-02	2012-08-03	Allergan, Inc.	Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
DE102006017600A1 (de) *	2006-02-09	2007-08-16	Friedel, Ruthard, Dr.	Nucleosidanaloga als Genexpressionsregulatoren bei Viren
EP1820804A1 (de) *	2006-02-20	2007-08-22	Humboldt-Universität zu Berlin	Lipophile Oligonukleotide
WO2007119624A1 (ja) *	2006-04-13	2007-10-25	National University Corporaton Hokkaido University	抗ヘルペスウイルス活性を有するヌクレオシド誘導体
JP2010500011A (ja)	2006-08-08	2010-01-07	ガンサーハートマン	５’リン酸オリゴヌクレオチドの構造および使用
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
US9738680B2 (en)	2008-05-21	2017-08-22	Rheinische Friedrich-Wilhelms-Universität Bonn	5′ triphosphate oligonucleotide with blunt end and uses thereof
EP2508530A1 (de)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
KR102072041B1 (ko)	2011-12-22	2020-01-31	앨리오스 바이오파마 인크.	치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
EP2712870A1 (de)	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
GB201410693D0 (en)	2014-06-16	2014-07-30	Univ Southampton	Splicing modulation
WO2016033424A1 (en)	2014-08-29	2016-03-03	Genzyme Corporation	Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
CN107109411B (zh)	2014-10-03	2022-07-01	冷泉港实验室	核基因输出的定向增加
CN108603230A (zh)	2015-10-09	2018-09-28	南安普敦大学	基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en)	2015-12-14	2021-08-24	Stoke Therapeutics, Inc.	Antisense oligomers and uses thereof
CN116059236A (zh)	2015-12-14	2023-05-05	冷泉港实验室	用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
KR20260009385A (ko)	2017-08-25	2026-01-19	스톡 테라퓨틱스, 인크.	병태 및 질환 치료용 안티센스 올리고머
JP2021523227A (ja)	2018-05-04	2021-09-02	ストークセラピューティクス，インク．	コレステリルエステル蓄積症の処置のための方法及び組成物
CA3098623A1 (en)	2018-05-07	2019-11-14	Alnylam Pharmaceuticals, Inc.	Extrahepatic delivery
CN108822174A (zh) *	2018-08-29	2018-11-16	上海兆维科技发展有限公司	新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法
KR20210134003A (ko)	2019-02-27	2021-11-08	스톡 테라퓨틱스, 인크.	병태 및 질환의 치료를 위한 안티센스 올리고머
IL293327B2 (en) *	2019-11-27	2026-04-01	Alnylam Pharmaceuticals Inc	Synthesis of 3'-RNA oligonucleotides
US12338437B2 (en)	2020-05-11	2025-06-24	Stoke Therapeutics, Inc.	OPA1 antisense oligomers for treatment of conditions and diseases
WO2024153166A1 (zh) *	2023-01-20	2024-07-25	石药集团中奇制药技术（石家庄）有限公司	一种经修饰的核苷单体及双链核糖核酸

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR927003044A (ko)	1990-01-11	1992-12-17	크리스토퍼 케이. 미라벨리	Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
DE4037363A1 (de)	1990-04-09	1991-10-10	Europ Lab Molekularbiolog	2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
DE4110085A1 (de) *	1991-03-27	1992-10-01	Boehringer Ingelheim Int	2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
US5214135A (en) *	1991-08-30	1993-05-25	Chemgenes Corporation	N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides

1993
- 1993-07-20 AT AT93917287T patent/ATE256143T1/de not_active IP Right Cessation
- 1993-07-20 EP EP02076058A patent/EP1223173B1/de not_active Expired - Lifetime
- 1993-07-20 DE DE69333842T patent/DE69333842T2/de not_active Expired - Lifetime
- 1993-07-20 JP JP6504646A patent/JP3015464B2/ja not_active Expired - Lifetime
- 1993-07-20 AU AU46849/93A patent/AU4684993A/en not_active Abandoned
- 1993-07-20 EP EP93917287A patent/EP0651759B1/de not_active Expired - Lifetime
- 1993-07-20 CA CA002140428A patent/CA2140428C/en not_active Expired - Lifetime
- 1993-07-20 AT AT02076058T patent/ATE299509T1/de not_active IP Right Cessation
- 1993-07-20 WO PCT/US1993/006807 patent/WO1994002501A1/en not_active Ceased
- 1993-07-20 DE DE69333344T patent/DE69333344T2/de not_active Expired - Lifetime
1997
- 1997-07-18 JP JP9194153A patent/JPH1087689A/ja active Pending
1999
- 1999-10-15 JP JP11293153A patent/JP2000095793A/ja not_active Ceased

Also Published As

Publication number	Publication date
DE69333842D1 (de)	2005-08-18
DE69333842T2 (de)	2006-04-27
JPH07508042A (ja)	1995-09-07
JP3015464B2 (ja)	2000-03-06
EP0651759B1 (de)	2003-12-10
EP1223173A2 (de)	2002-07-17
ATE299509T1 (de)	2005-07-15
CA2140428C (en)	2003-07-08
JPH1087689A (ja)	1998-04-07
EP0651759A1 (de)	1995-05-10
JP2000095793A (ja)	2000-04-04
EP1223173B1 (de)	2005-07-13
CA2140428A1 (en)	1994-02-03
WO1994002501A1 (en)	1994-02-03
EP1223173A3 (de)	2003-04-16
DE69333344T2 (de)	2004-10-07
DE69333344D1 (de)	2004-01-22
EP0651759A4 (de)	1995-10-25
AU4684993A (en)	1994-02-14

Legal Events

Date	Code	Title	Description
2004-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69333344D1 (de)	2004-01-22	2'-0-alkyl-nukleoside und-phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen
GB2228479B (en)	1993-10-20	2',3'-dideoxy purine nucleosides and process for the preparation thereof
DE59100830D1 (de)	1994-02-24	Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
ATE73758T1 (de)	1992-04-15	2,2-difluorcyclopropylethanderivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel.
EP0266168A3 (de)	1990-10-03	Zusammensetzungen und Verfahren zur Herstellung von Oligonukleotiden, deren 5' Ende phosphoryliert ist
KR960009930B1 (en)	1996-07-25	5'-phosphonates of 3'-azido-2,'3'-dideoxynucleosides
NO171641C (no)	1993-04-14	Analogifremgangsmaate for fremstilling av 6-substituert-2',3'-dideoksynukleosider
DE3884644D1 (de)	1993-11-11	Verfahren zur Herstellung von 5'-Inosinsäure.
DE3789466D1 (de)	1994-05-05	3,7-Disubstituierte-3-Cephemverbindungen und Verfahren zu ihrer Herstellung.
FI945322L (fi)	1995-05-16	Menetelmä 2',3'-didehydro-2',3'-dideoksinukleosidien laajamittaista valmistusta varten
FI885094A7 (fi)	1989-05-08	Menetelmä terapeuttisesti käyttökelpoisen 2',3'-dideoksi-3'-fluoripyrimidiini- tai -puriininukleosidin valmistamiseksi
DE3887212D1 (de)	1994-03-03	Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
IE45285L (en)	1977-12-03	Polyribonucleotides.
DE59004582D1 (de)	1994-03-24	1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin.
DE69004042D1 (de)	1993-11-25	2,4-Pentandion-1,5-Disulfonsäure und Verfahren zu ihrer Herstellung.
KR960701075A (ko)	1996-02-24	신규 2'-메틸리덴 뉴클레오티드 화합물, 그의 제조 방법 및 그의 약학적 용도[novel 2'-methylidenenucleotide compound, process for producing the same, and pharmaceutical use thereof]
DE3874496D1 (de)	1992-10-15	Verfahren zur herstellung von 4,4'-dibrombiphenyl.
DE69206765D1 (de)	1996-01-25	Verfahren zur herstellung von 2',3'-dideoxy-beta-nucleosiden
DE69628424D1 (de)	2003-07-03	Verfahren zur herstellung von nukleosid-analogen
DE3887293D1 (de)	1994-03-03	Si, Si'-Diorganyl-N-alkyl-tetrachlor-disilazane und Verfahren zu ihrer Herstellung.
IL93001A0 (en)	1990-09-17	Purine nucleosides and nucleotides,processes for the preparation thereof and pharmaceutical compositions containing the same
DE3887710D1 (de)	1994-03-24	1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)Thymine und Verfahren zu deren Herstellung.
JPS56142296A (en)	1981-11-06	Adenosine derivative and its preparation
NO910607D0 (no)	1991-02-15	Fremgangsmaate for fremstilling av 3'-fluor-nukleosidanaloger.
EP0406436A4 (en)	1992-04-22	Process for preparing 5'-inosinic acid